-
This Psychedelics Company Is Undertaking A 1:50 Reverse Stock Split To Enter NASDAQ
Thursday, September 15, 2022 - 2:36pm | 356Read More...The psychedelics landscape changes quickly. Whether large or small, every biotech company is looking for ways to further advance their research and product & services commercialization. Whether forward or back, stock splits are not intended to, nor should they, change the actual...
-
Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest EPS Growth Forecast For Next 5 Years
Monday, September 14, 2015 - 4:53am | 152Read More...Below are the top mid-cap biotechnology stocks on the NYSE and the NASDAQ in terms of EPS growth forecast for the next five years. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) earnings per share growth forecast for the next five years is 46.09 percent. Alnylam Pharmaceuticals' trailing-twelve-...
-
Top 4 Small-Cap Stocks In The Biotechnology Industry With The Highest EPS
Thursday, May 28, 2015 - 4:27am | 140Read More...Below are the top small-cap biotechnology stocks on the NYSE and the NASDAQ in terms of earnings per share. The trailing-twelve-month earnings per share at Epirus Biopharmaceuticals Inc (NASDAQ: EPRS) is $24.05. Epirus Biopharmaceuticals' growth forecast the current year is 92.30 percent. The...
-
Top 4 Small-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio
Tuesday, February 3, 2015 - 5:32am | 118Read More...Below are the top small-cap biotechnology stocks on the NYSE and the NASDAQ in terms of PEG ratio. Calithera Biosciences, Inc. (NASDAQ: CALA) has a PEG ratio of 0.02. Calithera Biosciences' trailing-twelve-month EPS is $16.29. PDL BioPharma, Inc. (NASDAQ: PDLI) has a PEG ratio of 0.27. PDL...
-
Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest Operating Margin
Thursday, August 21, 2014 - 4:57am | 116Read More...Below are the top biotechnology stocks on the NASDAQ in terms of operating margin. The trailing-twelve-month operating margin at PDL BioPharma (NASDAQ: PDLI) is 90.90%. PDL BioPharma's ROA for the same period is 51.00%. The trailing-twelve-month operating margin at Enzon Pharmaceuticals (NASDAQ:...
-
Top 4 Stocks In The Biotechnology Industry With The Highest Revenue
Thursday, August 7, 2014 - 4:24am | 113Read More...Below are the biotechnology stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Amgen (NASDAQ: AMGN) is $19.46 billion. Amgen's profit margin for the same period is 25.74%. The trailing-twelve-month revenue at Gilead Sciences (NASDAQ: GILD) is $17.44 billion...
-
Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest PEG Ratio
Thursday, July 10, 2014 - 4:51am | 101Read More...Below are the top biotechnology stocks on the NASDAQ in terms of PEG ratio. Aratana Therapeutics (NASDAQ: PETX) has a PEG ratio of 0.30. Aratana Therapeutics' trailing-twelve-month revenue is $0.30 million. Enzymotec (NASDAQ: ENZY) has a PEG ratio of 0.36. Enzymotec's trailing-twelve-month profit...
-
Top 4 Stocks In The Biotechnology Industry With The Highest EPS
Wednesday, June 25, 2014 - 4:54am | 121Read More...Below are the top biotechnology stocks on the NYSE and the NASDAQ in terms of earnings per share. The trailing-twelve-month earnings per share at Portola Pharmaceuticals (NASDAQ: PTLA) is $9.52. Portola Pharma's revenue for the same period is $9.80 million. The trailing-twelve-month earnings per...
-
Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS
Friday, May 9, 2014 - 4:48am | 119Read More...Below are the top biotechnology stocks on the NASDAQ in terms of earnings per share. The trailing-twelve-month earnings per share at bluebird bio (NASDAQ: BLUE) is $18.89. bluebird bio's revenue for the same period is $13.90 million. The trailing-twelve-month earnings per share at Biogen Idec (...
-
Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest PEG Ratio
Wednesday, April 2, 2014 - 4:29am | 102Read More...Below are the top biotechnology stocks on the NASDAQ in terms of PEG ratio. PDL BioPharma (NASDAQ: PDLI) has a PEG ratio of 0.35. PDL BioPharma's trailing-twelve-month revenue is $442.90 million. Enzymotec (NASDAQ: ENZY) has a PEG ratio of 0.43. Enzymotec's trailing-twelve-month operating margin...
-
Biotech ETFs Come Back Down To Earth
Thursday, March 27, 2014 - 4:29pm | 483Read More...Biotech stocks have been one of the hottest sectors of the market over the last several years and many exchange traded funds have benefitted greatly from their success. The two largest ETFs in this space are the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSE:...
-
Top 4 Large-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio
Wednesday, February 26, 2014 - 5:18am | 105Read More...Below are the top large-cap biotechnology stocks on the NYSE and the NASDAQ in terms of PEG ratio. Gilead Sciences (NASDAQ: GILD) has a PEG ratio of 0.62. Gilead Sciences' trailing-twelve-month revenue is $11.20 billion. Celgene (NASDAQ: CELG) has a PEG ratio of 0.93. Celgene's trailing-twelve-...
-
Top 4 Small-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio
Tuesday, October 22, 2013 - 4:29am | 115Read More...Below are the top small-cap biotechnology stocks on the NYSE and the NASDAQ in terms of PEG ratio. Idenix Pharmaceuticals (NASDAQ: IDIX) has a PEG ratio of 0.11. Idenix's trailing-twelve-month revenue is $33.54 million. Exelixis (NASDAQ: EXEL) has a PEG ratio of 0.17. Exelixis had $351.97 million...
-
Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter
Wednesday, May 15, 2013 - 4:13am | 133Read More...Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter. Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion. Amgen (NASDAQ: AMGN) is...
-
Top 4 NYSE Stocks In The Biotechnology Industry With The Highest ROA
Friday, December 7, 2012 - 4:44am | 124Read More...Below are the top biotechnology stocks on the NYSE in terms of return on assets. The trailing-twelve-month return on assets at Charles River Laboratories International (NYSE: CRL) is 7.63%. Charles River Laboratories' operating margin for the same period is 16.89%. The trailing-twelve-month...
